Clinical Evaluation of the Long-Term Effects of Contact Lens Care Systems

NCT ID: NCT00813761

Last Updated: 2018-06-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

473 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-01

Study Completion Date

2009-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare two marketed contact lens care solutions in regards to comfort and ocular health.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

02Optix CL and ReNu MPS with SICS

O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution

Group Type OTHER

O2Optix contact lens

Intervention Type DEVICE

control contact lens to be worn daily for approximately 7 months for entire length of study.

ReNu MultiPlus Multi-Purpose Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

Proclear CL and ReNu MPS with SICS

Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution

Group Type OTHER

Proclear contact lens

Intervention Type DEVICE

control contact lens to be worn for entire length of study.

ReNu MultiPlus Multi-Purpose Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

02Optix CL and Clear Care LCS with SICS

O2Optix contact lens and Clear Care lens care solution subject

Group Type OTHER

O2Optix contact lens

Intervention Type DEVICE

control contact lens to be worn daily for approximately 7 months for entire length of study.

Clear Care Cleaning and Disinfecting Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

Proclear CL and Clear Care LCS with SICS

Proclear contact lens and Clear Care lens care solution

Group Type OTHER

Proclear contact lens

Intervention Type DEVICE

control contact lens to be worn for entire length of study.

Clear Care Cleaning and Disinfecting Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

02Optix CL and ReNu MPS without SICS

O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution

Group Type OTHER

O2Optix contact lens

Intervention Type DEVICE

control contact lens to be worn daily for approximately 7 months for entire length of study.

ReNu MultiPlus Multi-Purpose Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

Proclear CL and ReNu MPS without SICS

Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution

Group Type OTHER

Proclear contact lens

Intervention Type DEVICE

control contact lens to be worn for entire length of study.

ReNu MultiPlus Multi-Purpose Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

02Optix CL and Clear Care LCS without SICS

O2Optix contact lens and Clear Care lens care solution

Group Type OTHER

O2Optix contact lens

Intervention Type DEVICE

control contact lens to be worn daily for approximately 7 months for entire length of study.

Clear Care Cleaning and Disinfecting Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

Proclear CL and Clear Care LCS without SICS

Proclear contact lens and Clear Care lens care solution

Group Type OTHER

Proclear contact lens

Intervention Type DEVICE

control contact lens to be worn for entire length of study.

Clear Care Cleaning and Disinfecting Solution

Intervention Type DEVICE

lens solution for overnight lens disinfection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

O2Optix contact lens

control contact lens to be worn daily for approximately 7 months for entire length of study.

Intervention Type DEVICE

Proclear contact lens

control contact lens to be worn for entire length of study.

Intervention Type DEVICE

ReNu MultiPlus Multi-Purpose Solution

lens solution for overnight lens disinfection

Intervention Type DEVICE

Clear Care Cleaning and Disinfecting Solution

lens solution for overnight lens disinfection

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years old.
* Signed Informed Consent and Investigator to record this on Case Report Form (CRF) in appropriate space.
* Require a visual correction in both eyes (monovision allowed but not monofit).
* Have a contact lens spherical distance requirement between +6.00D and -9.00D in both eyes.
* Astigmatism of 1.00D or less in the better eye and 1.50D or less in the other eye.
* Be correctable to a visual acuity of 20/30 (6/9) or better in each eye.
* Have normal eyes with no evidence of abnormality or disease.

Exclusion Criteria

* Requires concurrent ocular medication.
* Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
* Clinically significant corneal edema, corneal vascularisation, tarsal abnormalities, bulbar injection or any other abnormality of the cornea that would contraindicate contact lens wear.
* Worn lenses on an extended wear basis in the last 3 months.
* Diabetic.
* Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
* Polymethyl methacrylate (PMMA) or rigid gas-permeable (RGP) lens wear in the previous 8 weeks.
* Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study.
* Abnormal lacrimal secretions.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

North Little Rock, Arkansas, United States

Site Status

Campbell, California, United States

Site Status

Cupertino, California, United States

Site Status

Laguna Niguel, California, United States

Site Status

Mission Viejo, California, United States

Site Status

San Clemente, California, United States

Site Status

Colorado Springs, Colorado, United States

Site Status

Bloomington, Illinois, United States

Site Status

Neodesha, Kansas, United States

Site Status

Raytown, Missouri, United States

Site Status

Warrensburg, Missouri, United States

Site Status

Florence, New Jersey, United States

Site Status

Chagrin Falls, Ohio, United States

Site Status

Warren, Ohio, United States

Site Status

Kittanning, Pennsylvania, United States

Site Status

Moon Township, Pennsylvania, United States

Site Status

Nanticoke, Pennsylvania, United States

Site Status

State College, Pennsylvania, United States

Site Status

Warwick, Rhode Island, United States

Site Status

Chamberlain, South Dakota, United States

Site Status

Bartlett, Tennessee, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Burlington, Vermont, United States

Site Status

Midlothian, Virginia, United States

Site Status

Virginia Beach, Virginia, United States

Site Status

Aston Triangle, Birmingham, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-4522

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.